This blog belongs to: VERALAND

Monday, December 21, 2009

Noradrenergic activity in rat brain during rapid eye movement sleep deprivation and rebound sleep

HOME PAGE


Am J Physiol Regul Integr Comp Physiol 268: R1456-R1463, 1995; 0363-6119/95 $5.00

AJP - Regulatory, Integrative and Comparative Physiology, Vol 268, Issue 6 1456-R1463, Copyright © 1995 by American Physiological Society

Noradrenergic activity in rat brain during rapid eye movement sleep deprivation and rebound sleep

T. Porkka-Heiskanen, S. E. Smith, T. Taira, J. H. Urban, J. E. Levine, F. W. Turek and D. Stenberg Department of Physiology, University of Helsinki, Finland.

Noradrenergic locus ceruleus neurons are most active during waking and least active during rapid eye movement (REM) sleep.

We expected REM sleep deprivation (REMSD) to increase norepinephrine utilization and activate the tyrosine hydroxylase (TH) gene critical for norepinephrine production.

Male Wistar rats were deprived of REM sleep with the platform method.

Rats were decapitated after 8, 24, or 72 h on small (REMSD) or large (control) platforms or after 8 or 24 h of rebound sleep after 72 h of the platform treatment.

During the first 24 h, norepinephrine concentration, measured by high-performance liquid chromatography/electrochemical detection, was lower in the neocortex, hippocampus, and posterior hypothalamus in REMSD rats than in large-platform controls.

After 72 h of REMSD, TH mRNA, measured by in situ hybridization, was increased in the locus ceruleus and norepinephrine concentrations were increased.

Polygraphy showed that small-platform treatment caused effective and selective REMSD.

Serum corticosterone measurement by radioimmunoassay indicated that the differences found in norepinephrine and TH mRNA were not due to differences in stress between the treatments.

The novel finding of sleep deprivation-specific increase in TH gene expression indicates an important mechanism of adjusting to sleep deprivation.

Norepinephrine
From Wikipedia, the free encyclopedia

Noradrenaline (BAN) (abbreviated NA or NAd) or norepinephrine (INN) (abbreviated norepi or NE) is a catecholamine with dual roles as a hormone and a neurotransmitter.[2]
As a stress hormone, norepinephrine affects parts of the brain where attention and responding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle.
However, when norepinephrine acts as a drug it will increase blood pressure by its prominent increasing effects on the vascular tone from α-adrenergic receptor activation. The resulting increase in vascular resistance triggers a compensatory reflex that overcomes its direct stimulatory effects on the heart, called the baroreceptor reflex, which results in a drop in heart rate called reflex bradycardia.
Norepinephrine is synthesized from dopamine by dopamine β-hydroxylase.[3] It is released from the adrenal medulla into the blood as a hormone, and is also a neurotransmitter in the central nervous system and sympathetic nervous system where it is released from noradrenergic neurons. The actions of norepinephrine are carried out via the binding to adrenergic receptors.

Mechanism
Norepinephrine is synthesized from tyrosine as a precursor, and packed into synaptic vesicles. It performs its action by being released into the synaptic cleft, where it acts on adrenergic receptors, followed by the signal termination, either by degradation of norepinephrine, or by uptake by surrounding cells.

http://en.wikipedia.org/wiki/Norepinephrine

Thursday, October 29, 2009

Corticotropin-Releasing Hormone (CRH) Downregulates the Function of Its Receptor (CRF1)

HOME PAGE

Corticotropin-Releasing Hormone (CRH) Downregulates the Function of Its Receptor (CRF1) and Induces CRF1 Expression in Hippocampal and Cortical Regions of the Immature Rat Brain


Kristen L. Brunsona, Dimitri E. Grigoriadisb, Marge T. Lorangb and Tallie Z. Baramc, a
a Department of Anatomy and Neurobiology, University of California at Irvine, Irvine, California, 92697

c Department of Pediatrics, University of California at Irvine, Irvine, California, 92697
b Neurocrine Biosciences Inc. La Jolla, California, 92121
Received 26 October 2001;
accepted 27 March 2002. ;

Available online 2 July 2002.

Abstract

In addition to regulating the neuroendocrine stress response, corticotropin-releasing hormone (CRH) has been implicated in both normal and pathological behavioral and cognitive responses to stress.

CRH-expressing cells and their target neurons possessing CRH receptors (CRF1 and CRF2) are distributed throughout the limbic system, but little is known about the regulation of limbic CRH receptor function and expression, including regulation by the peptide itself.

Because CRH is released from limbic neuronal terminals during stress, this regulation might play a crucial role in the mechanisms by which stress contributes to human neuropsychiatric conditions such as depression or posttraumatic stress disorder.

Therefore, these studies tested the hypothesis that CRH binding to CRF1 influenced the levels and mRNA expression of this receptor in stress-associated limbic regions of immature rat.

Binding capacities and mRNA levels of both CRF1 and CRF2 were determined at several time points after central CRH administration.

CRH downregulated CRF1 binding in frontal cortex significantly by 4 h.

This transient reduction (no longer evident at 8 h) was associated with rapid increase of CRF1 mRNA expression, persisting for >8 h.

Enhanced CRF1 expression—with a different time course—occurred also in hippocampal CA3, but not in CA1 or amygdala, CRF2 binding and mRNA levels were not altered by CRH administration.

To address the mechanisms by which CRH regulated CRF1, the specific contributions of ligand–receptor interactions and of the CRH-induced neuronal stimulation were examined.

Neuronal excitation without occupation of CRF1 induced by kainic acid, resulted in no change of CRF1 binding capacity, and in modest induction of CRF1 mRNA expression.

Furthermore, blocking the neuroexcitant effects of CRH (using pentobarbital) abolished the alterations in CRF1 binding and expression.

These results indicate that CRF1 regulation involves both occupancy of this receptor by its ligand, as well as “downstream” cellular activation and suggest that stress-induced perturbation of CRH–CRF1 signaling may contribute to abnormal neuronal communication after some stressful situations.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFG-466CG3D-7&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1070019700&_rerunOrigin=scholar.google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=ccddf7fb2570ed531ae236ebf17a4ea0

Tuesday, October 27, 2009

CRH Enhances Retention of a Spatial Memory

HOME PAGE

Performing your original search, crh memory, in PubMed will retrieve 54 records.

Neurobiol Learn Mem. 2008 May;89(4):370-8. Epub 2007 Dec 20.

Post-training administration of corticotropin-releasing hormone (CRH) enhances retention of a spatial memory through a noradrenergic mechanism in male rats.

Row BW, Dohanich GP.
Department of Pediatrics, Kosair Children's Hospital Research Institute, University of Louisville, Louisville, KY 40202, USA.
Hormones released in response to stress play important roles in cognition. In the present study, the effects of the stress peptide, corticotropin-releasing hormone (CRH), on spatial reference memory were assessed following post-training administration. Adult Long-Evans male rats were trained for 6 days on a standard water maze task of reference memory in which animals must learn and remember the fixed location of a hidden, submerged platform. Each day, immediately following three training trials, rats received bilateral infusions of CRH into the lateral ventricles over a range of doses (0.1, 0.33, 1.0, 3.3 microg) or a vehicle solution. Post-training infusions of CRH improved retention as indicated by significantly shorter latencies and path lengths to locate the hidden platform on the first training (retention) trial of days 2 and 3. Additionally, post-training administration of CRH increased spatial bias during probe trials as measured by proximity to the platform location. CRH did not enhance performance on retention or probe trials when administered 2h after daily training indicating that CRH facilitated consolidation specifically. The effects of CRH were attenuated by intraventricular co-administration of the beta-adrenergic antagonist, propanolol, at bilateral doses that had no effect on retention alone (0.1, 1.0 microg). Results indicate that post-training administration of CRH enhanced spatial memory as measured in a water maze, and this effect was mediated, at least partly, by a noradrenergic mechanism.
PMID: 18086539 [PubMed - indexed for MEDLINE]
Publication Types, MeSH Terms, Substances

http://www.ncbi.nlm.nih.gov/pubmed/18086539

Norepinephrine

From Wikipedia, the free encyclopedia

Noradrenaline (BAN) (abbreviated NA or NAd) or norepinephrine (INN) (abbreviated norepi or NE) is a catecholamine with dual roles as a hormone and a neurotransmitter.[2]

As a stress hormone, norepinephrine affects parts of the brain where attention and responding actions are controlled. Along with epinephrine, norepinephrine also underlies the fight-or-flight response, directly increasing heart rate, triggering the release of glucose from energy stores, and increasing blood flow to skeletal muscle.
However, when norepinephrine acts as a drug it will increase blood pressure by its prominent increasing effects on the vascular tone from α-adrenergic receptor activation. The resulting increase in vascular resistance triggers a compensatory reflex that overcomes its direct stimulatory effects on the heart, called the baroreceptor reflex, which results in a drop in heart rate called reflex bradycardia.
Norepinephrine is synthesized from dopamine by dopamine β-hydroxylase.[3] It is released from the adrenal medulla into the blood as a hormone, and is also a neurotransmitter in the central nervous system and sympathetic nervous system where it is released from noradrenergic neurons. The actions of norepinephrine are carried out via the binding to adrenergic receptors.

SEE MORE! at:

http://en.wikipedia.org/wiki/Norepinephrine

SEE ALSO:

Dopamine
http://en.wikipedia.org/wiki/Dopamine

Prolactin
http://en.wikipedia.org/wiki/Prolactin


Copyright © 1999 Elsevier Science Inc. All rights reserved.
Original Articles

Changes in hippocampal theta following intrahippocampal corticotropin-releasing hormone (CRH) infusions in the rat


Rudie Kortekaas, , a, Brenda Costalla and James W. Smythea
a Department of Pharmacology, University of Bradford, Bradford, UK

Received 7 October 1998;
revised 2 February 1999;
accepted 2 February 1999.
Available online 1 June 1999.

Abstract

Hippocampal theta activity is a large amplitude, sinusoidal wave that occurs during attentive immobility and exploratory behaviour in the rat, and it is thought to be involved in memory formation.

Recent reports suggest that corticotropin-releasing hormone (CRH) has pro-mnemonic effects in rodents.

(A mnemonic device (pronounced /nɨˈmɒnɨk/[1]) is a mind memory and/or learning aid. Commonly, mnemonics are verbal—such as a very short poem or a special word used to help a person remember something - wikipedia)

Because memory-enhancing substances/manipulations generally alter either theta frequencies or amplitudes, these variables were monitored in urethane-anaesthetised rats following intra-hippocampal infusions of CRH.

Adult male, Lister hooded rats were implanted with a hippocampal recording electrode and a guide cannula, both aimed at the dentate gyrus.

When CRH was infused into the hippocampus, the main change in the hippocampal EEG was a slow onset increase in the amplitude of spontaneous theta and, paradoxically, a significant decrease in the amount of time spent displaying theta.

These data suggest that CRH has the ability to modulate ongoing hippocampal theta, but, considering the slow effect, the involvement of hippocampal CRH receptors is suspect. Regardless of locus, the described electrophysiological changes suggest that hippocampal cholinergic systems may play a role in the memory-enhancing effects of CRH.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6SYT-3WKY1S9-6&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1066745569&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=ed79d8585decfce3507a3675c4a5f584

Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris

HOME PAGE

Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris.

Br J Dermatol. 2009 Feb;160(2):345-52. Epub 2008 Dec 10.
Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC.


Centre of Dermatovenereology, Vilnius University Hospital, Santariskiu Klinikos, Vilnius, Lithuania.

Comment in:

Br J Dermatol. 2009 Feb;160(2):229-32.

BACKGROUND:

The sebaceous gland exhibits an independent peripheral endocrine function and expresses receptors for neuropeptides.

Previous reports have confirmed the presence of a complete corticotropin-releasing hormone (CRH) system in human sebocytes in vitro.

The capability of hypothalamic CRH to induce lipid synthesis, induce steroidogenesis and interact with testosterone and growth hormone implicates a possibility of its involvement in the clinical development of acne.

OBJECTIVES:

The purpose of the study was to detect expression changes of CRH/CRH binding protein (CRHBP)/CRH receptors (CRHRs) in acne-involved skin, especially in the sebaceous glands.

METHODS:

Expression of CRH/CRHBP/CRHRs was analysed by immunohistochemistry in biopsies from facial skin of 33 patients with acne, noninvolved thigh skin of the same patients and normal skin of eight age-matched healthy volunteers.

RESULTS:

Very strong positive reaction for CRH was observed in acne-involved skin in all types of sebaceous gland cells, irrespective of their differentiation stage, whereas in noninvolved and normal skin sebaceous glands exhibited a weaker CRH staining depending upon the differentiation stage of sebocytes.

The strongest reaction for CRHBP (binding protein) in acne-involved sebaceous glands was in differentiating sebocytes.

CRHR-1 and CRHR-2 exhibited the strongest expression in sweat glands and sebaceous glands, respectively.

CONCLUSIONS:

Expression of the complete CRH system is abundant in acne-involved skin, especially in the sebaceous glands, possibly activating pathways which affect immune and inflammatory processes leading to the development and stress-induced exacerbation of acne.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=19077080%5Buid%5D
SEE ALSO (pdf file):

Differential Expression of a Cutaneous Corticotropin-
Releasing Hormone System
Copyright © 2005 Elsevier Ltd All rights reserved.

Neuroimmunoendocrine circuitry of the ‘brain-skin connection’

Ralf Pausa, , Theoharis C. Theoharidesb and Petra Clara Arckc,

aDepartment of Dermatology, University Hospital Schleswig-Holstein, Campus Lübeck, University of Lübeck, D-23538 Lübeck, Germany

bDepartments of Pharmacology & Experimental Therapeutics, Biochemistry and Internal Medicine, Tufts University School of Medicine, Boston, MA 02111, USA

cBiomedical Research Center, Charité – University Medicine Berlin, D-13353 Berlin, Germany
Available online 2 November 2005.

The skin offers an ideally suited, clinically relevant model for studying the crossroads between peripheral and systemic responses to stress.
A ‘brain–skin connection’ with local neuroimmunoendocrine circuitry underlies the pathogenesis of allergic and inflammatory skin diseases, triggered or aggravated by stress.
In stressed mice, corticotropin-releasing hormone (CRH), nerve growth factor, neurotensin, substance P and mast cells are recruited hierarchically to induce neurogenic skin inflammation, which inhibits hair growth.
The hair follicle is both a target and a source for immunomodulatory stress mediators, and has an equivalent of the hypothalamus–pituitary–adrenal axis.
Thus, the skin and its appendages enable the study of complex neuroimmunoendocrine responses that peripheral tissues launch upon stress exposure, as a basis for identifying new targets for therapeutic stress intervention.

Saturday, October 24, 2009

CRH and GPI-anchored Gas families are FUNGAL ANTIGENS

HOME PAGE

2007: Arroyo Javier; Sarfati Jaqueline; Baixench Marie Thérése; Ragni Enrico; Guillén Marivi; Rodriguez-Peña José Manuel; Popolo Laura; Latgé Jean Paul

The GPI-anchored Gas and Crh families are fungal antigens

Yeast (Chichester, England) 2007;24(4):289-96.

The cell wall is the first interface between a fungus and its extracellular environment.

Glycosyltransferases involved in the formation and dynamic remodelling of the polysaccharide network of the cell wall have recently been identified.

The best characterized ones belong to the
Gas family, which elongates beta(1,3)-glucans, and to the
Crh family, which are involved in the cross-linking of chitin to beta(1,6)-glucan. (SEE BELOW ON THE LARGE)

All these proteins carry a glycosylphosphatidylinositol (GPI) anchor. (SEE BELOW ON THE LARGE)

In this work, we show that recombinant soluble forms of Gas1-5 and Crh1p from Saccharomyces cerevisiae and their orthologous proteins Gel1-Gel2 and Crf1 from Aspergillus fumigatus are specifically recognized by antibodies present in the sera of patients with Aspergillus or Candida infections.

Quantification of the antibody titres against recombinant Gas/Gel and Crh/Crf proteins separated aspergilloma and candidiasis patients from non-infected individuals.

Cross-reactivity was seen between the antibody response of patients with aspergillosis and candidiasis towards the Gas/Gel and Crh/Crf proteins.

These results suggest that GPI-anchored cross-linking enzymes are relevant immunologically reactive constituents of the cell wall that may play a role during human fungal infections.

http://www.biomedexperts.com/Abstract.bme/17397107/The_GPI-anchored_Gas_and_Crh_families_are_fungal_antigens

The Corticotropin-Releasing Hormone (CRH) family of peptides

The 41-amino acid sequence of CRH was first discovered in sheep by Vale et al. in 1981

http://en.wikipedia.org/wiki/Corticotropin-releasing_hormone

CRH is a 41-amino acid peptide that was first isolated from the sheep hypothalamus.

It has since been found in a large variety of species with a high degree of sequence identity, emphasizing the importance of this hormone.

The human CRH gene consists of two exons separated by an intron in its 5' untranslated region. The rat and ovine CRH genes have the same organization. While CRH accounts for a large part of the corticotropin-releasing activity of extracts in the hypothalamus, it does not account for all of it.

In fact there appears to be a wider family featuring structurally related peptides, including sauvagine in amphibia, urotensin I in teleost fish and urocortin in mammals.

Urocortin is localizaed in the rat midbrain region, testis, cardiac myocytes, thymus, spleen, kidney and human reproductive tissues.

CRH-like activity is widely distributed in:
-central nervous system,
-adrenals,
-lungs,
-liver,
-stomach,
-pancreas,
-small intestine and
-reproductive tissues and in a variety of
-human tumours.

The following systems are affected by CRH through extrapituitary mechanisms:
-cardiovascular regulation,
-respiration,
-appetite control,
-glucose metabolism,
-immune function, and
-cognitive and motor behaviour.

Moreover, immunoreactive CRH found in reproductive tissues can exert a number of effects. It can participate in intrauterine inflammatory processes of early pregnancy.

Recently, two new members of the CRH neuropeptide family have been cloned:
-stress-copin-related peptide (SRP)/urocortin II and
-stresscopin (SCP)/urocotrtin III.

SRP/ urocortin III mRNA expression have been detected in the gastrointestinal tract, muscle, adrenal gland and skin.

CRH Receptors

CRH Receptors belong to the class II superfamily of "brain-gut" neuropeptide receptors, which all contain 7 transmembrane helical domanins and share considerable sequence identity with one another.

Currently there are 2 known classes of CRH receptors, termed type 1 and type 2, that have been cloned from a number of vertebrate species and are encoded by separate genes.

CRH-R1 shares 70% identity with CRH-R2 and both receptors are present in structurally distinct isoforms.

The CRH-R1 gene expresses multiple subtypes, 1alpha-h, which are produced by differential exon splicing.

Each CRH-R1 variant has a defect in its expression, binding or signalling characteristics; for example, CRH-R1 beta contains a 29-amino-acid insertion in its first intracellular loop, allowing only weak coupling to the stimulatory G-protein.

The CRH-R2 gene expresses 3 known subtypes, 2alpha, 2beta and 2epsilon, that are produced by the use of alternative 5" exons and hence differ only at the N-terminus, which forms part of the first extracellular domain.

CRH-R2 mRNA is mainly expressed in peripheral tissue, particularly in cardiac myocytes, lung, skeletal muscles, ovary and gastrointestinal tract.

In the brain, the highest densities are in the parvovetricular nucleus of the hypothalamus, the amygdala and the lateral septum.

More recently, in the diploid catfish species, a third CRH receptor (CRH-R3), has been identified. This novel CRH receptor is structurally closer to cat-fish CRH-R1 than CRh-R2 and binds with a 5-fold higher affinity than urotensin I abd sauvagne. CRH-R3 in the catfish is expressed in the pituitary gland, urophysis and brain.

This multiplicity is receptor subtypes and ligands provides for diversity of receptor expression and signalling.

CRH receptor sensitivity

Mammalian CRH-R1 receptors have an equal, yet high affinity for CRH, urocortin, sauvagne and urotensin I, while not showing any affinity for urocortin II or III.

In contrast, CRH-R2 receptors show a clear preference in their affinity for urocortin-like ligands.

Urocortins I, II and III, all show high-affinity binding to CRH-R2, while mammalian CRH binds weakly.

CRH receptors are highly promiscuous. Not only do they bind a number of different ligands, but they can also activate different G-alpha subunits. Due to the complex nature of mammalian cells, the precise details of the coupling of the CRH receptors to their cognate G-protein are unknown.

LAB YEAST-CRH EXPERIENCE:

To investigate such coupling, we have utilized a YEAST reporter strain in which the pheromone-response pathways were adapted to allow ligand-dependent signalling of heterologously G-proteins or or YEAST-mammalian chimaeric G-alpha proteins.

We expressed one representative of each family of CRH receptors (CRH-R1 alpha and CRH-R2 beta) within SCHIZOSACCHAROMYCES pombe cells.

(Schizosaccharomyces pombe, also called "fission yeast", is a species of yeast. It is used as a model organism in molecular and cell biology.) - wikipedia)
http://en.wikipedia.org/wiki/Schizosaccharomyces_pombe

Due to modifications of the cell, the CRH receptor subtypes were the only GPCRs present within the cell.

When the cells were challenged with exogenous CRH, we observed functional coupling and signalling of the CRH-R1 alpha receptor via Gas and Gai.
In contrast, urocortin I activated Gas and Gaq.

Urocortins II and III did not activate any G-proteins. Using cells transfected with CRH-R2b, we confirmed that urocortins II and III signal via this receptor subtype.

These results are as expected, since CRH has a high affinity for CRH-R1 receptors,
but only a low affinity for type 2 receptors.


Contained within this study, we investigated a number of different ligands, and made changes to
components within the Sz. pombe cells to allow a more accurate evaluation of CRH signalling.

From our results it is clear that CRH-receptor±G-protein coupling}signalling is far from simple,
and may occur in a ligand-dependent manner.

The understanding of the precise nature of CRH signalling for both receptor families and each receptor subtype is of paramount importance in understanding stress responses.

Intracellular signalling molecules

In many tissues (e.g. brain, heart, myometrium), stimulation of either type of CRH receptor by CRH or CRH-related peptides leads to the activation of adenylate cyclase and increased cAMP levels.

However, in certain tissues (i.e. testes, placenta), CRH is unable to activate the adenylate cyclase pathway, whereas it can stimulate alternative signalling cascades, such as stimulation of phosphoinositol hydrolysis, but with reduced efficacy.

As mentioned above, several studies in native tissues and artificial expression systems have demonstrated multiple G-protein activation, a finding that predicts activation of several different second messenger signals and suggests that CRH and CRH-related peptides can generate various responses in different target tissues.

Indeed, it has been shown thus far that the CRH receptors can modulate various intacellular signals, such as protein kinase.

Protein kinase, nitric oxide synthase, guanylate cyclase, prostaglandins, steroidogenic enzymes, FasL production and apoptosis.

The CRH-receptor±MAPK interaction appears to be of particular interest, since in some
cellular systems (myometrial or HEK cells overexpressing CRH receptors), urocortin or
sauvagine, but not CRH, can activate the p42}p44 MAPK system [47,48].

This effect appears to be mediated primarily, but not exclusively, via activation of the Gq±InsP$±PKC pathway.

Studies on G-protein activation and second messenger
production demonstrated that urocortin was significantly more potent than CRH in activating the Gq±InsP$±PKC pathway.

This shows the central role of the agonist±CRH-receptor±G-protein complex in determining activation of signalling cascades.

In contrast, in neuronal and hippocampal cells, both CRH and urocortin can activate the MAPK cascade, a signalling pathway that mediates the neuroprotective effects of these peptides
[49,50]; this appears to occur via activation of the Gs}adenylate cyclase system.

Without any doubt, many more studies are required to elucidate the signalling pathways that are influenced by the family of CRH peptides in different tissues.

SEE THE BOOK AT:

http://www.biochemsoctrans.org/bst/030/0428/0300428.pdf



Vol. 12, Issue 11, 3631-3643, November 2001

Signaling through Adenylyl Cyclase Is Essential for Hyphal Growth and Virulence in the Pathogenic Fungus Candida albicans

Cintia R. C. Rocha,* Klaus Schröppel, Doreen Harcus,* Anne Marcil,* Daniel Dignard,* Brad N. Taylor, David Y. Thomas,*§ Malcolm Whiteway,*§ and Ekkehard Leberer*¶

*Eukaryotic Genetics Group, Biotechnology Research Institute, National Research Council of Canada, Montreal, Quebec H4P 2R2, Canada; the Institute of Clinical Microbiology, Immunology, and Hygiene, University of Erlangen, D-91054 Erlangen, Germany; and the Departments of Anatomy and Cell Biology, §Biology, and Experimental Medicine, McGill University, Montreal, Canada

The human fungal pathogen Candida albicans switches from a budding yeast form to a polarized hyphal form in response to various external signals.

This morphogenetic switching has been implicated in the development of pathogenicity.

We have cloned the CaCDC35 gene encoding C. albicans adenylyl cyclase by functional complementation of the conditional growth defect of Saccharomyces cerevisiae cells with mutations in Ras1p and Ras2p.

It has previously been shown that these Ras homologues regulate adenylyl cyclase in yeast.

The C. albicans adenylyl cyclase is highly homologous to other fungal adenylyl cyclases but has less sequence similarity with the mammalian enzymes.

C. albicans cells deleted for both alleles of CaCDC35 had no detectable cAMP levels, suggesting that this gene encodes the only adenylyl cyclase in C. albicans.

The homozygous mutant cells were viable but grew more slowly than wild-type cells and were unable to switch from the yeast to the hyphal form under all environmental conditions that we analyzed in vitro. Moreover, this morphogenetic switch was completely blocked in mutant cells undergoing phagocytosis by macrophages.

However, morphogenetic switching was restored by exogenous cAMP.

On the basis of epistasis experiments, we propose that CaCdc35p acts downstream of the Ras homologue CaRas1p.

These epistasis experiments also suggest that the putative transcription factor Efg1p and components of the hyphal-inducing MAP kinase pathway depend on the function of CaCdc35p in their ability to induce morphogenetic switching.

Homozygous cacdc35 cells were unable to establish vaginal infection in a mucosal membrane mouse model and were avirulent in a mouse model for systemic infections.

These findings suggest that fungal adenylyl cyclases and other regulators of the cAMP signaling pathway may be useful targets for antifungal drugs.

http://www.molbiolcell.org/cgi/content/abstract/12/11/3631

Cyclic adenosine monophosphate (cAMP)
From Wikipedia, the free encyclopedia

Cyclic adenosine monophosphate (cAMP, cyclic AMP or 3'-5'-cyclic adenosine monophosphate) is a second messenger important in many biological processes. cAMP is derived from adenosine triphosphate (ATP) and used for intracellular signal transduction in many different organisms, conveying the cAMP-dependent pathway.

cAMP is synthesised from ATP by adenylyl cyclase located at the cell membranes.
cAMP and its associated kinases function in several biochemical processes, including the regulation of glycogen, sugar, and lipid metabolism.

Some research has suggested that a deregulation of cAMP pathways and an aberrant activation of cAMP-controlled genes is linked to the growth of some cancers.

http://en.wikipedia.org/wiki/Cyclic_adenosine_monophosphate

Copyright © 1997 Published by Elsevier Science B.V.

Glycosyl-phosphatidylinositol anchored membrane enzymes (GPI anchors)

Nigel M. Hooper,
School of Biochemistry and Molecular Biology, The University of Leeds, Leeds LS2 9JT, UK
Received 20 October 1996; accepted 23 July 1997. ; Available online 11 March 1999.

Abstract

Several mammalian enzymes are anchored to the outer surface of the plasma membrane by a covalently attached glycosyl-phosphatidylinositol (GPI) structure.

These include acetylcholinesterase, alkaline phosphatase, membrane dipeptidase and 5′-nucleotidase.

All GPI anchors determined to date have the conserved core structure ethanolamine-PO4-6Manα1-2Manα1-6Manα1-4GlcNH2α1-6myo-inositol-1-PO−4 lipid.

In most mammalian GPI anchors the lipid is 1-alkyl-2-acyl-glycerol, although in porcine membrane dipeptidase it is diacylglycerol.

Attached to the conserved core are various side chain residues that appear to be either protein- or tissue-specific.

In addition to membrane attachment, a GPI anchor may confer additional properties on the protein, such as the susceptibility to cleavage by phospholipases and the potential to cluster in detergent-insoluble domains.

GPI anchors can also act as intracellular targeting signals, in transmembrane signalling, in the clathrin-independent endocytic process of potocytosis and as hormone mediators.

Thus, a GPI anchor can confer additional properties on enzymes that may be important in their physiological and pathophysiological functioning.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T57-3W0K17R-2&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1062001067&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=05e1d002f735043de9be6fd944c73467

Resistance to candidiasis and macrophage activity in chitin-treated mice

Aitor Rementeríaa, Fernando Abaituaa, Roberto García-Tobalinaa, Fernando Hernandoa, José Pontóna, María Jesús Sevillaa
a Departamento de Inmunología, Microbiología y Parasitología, Universidad del País Vasco, Apdo. 644, Bilbao, E-48080, Spain

The effect of chitin, a polysaccharide of the cell wall of Candida albicans, on both the survival of C. albicans infected mice and the activity of the murine peritoneal macrophages has been studied. Pretreatment of mice with 30 mg kg−1C. albicans chitin enhanced the survival of the infected animals. The protective effect was concomitant with an enhancement of both phagocytic and candidacidal activities of the peritoneal macrophages. Chitin by itself did not induce the nitric oxide (NO) synthase in the macrophages, which remained at a level similar to that shown by the macrophages from untreated animals. The administration of 10 mg kg−1C. albicans chitin diminished the long term survival of the infected animals. This effect was coincident with a lower candidacidal activity and NO production by the macrophages of the chitin treated and infected animals, compared to the untreated infected animals.

Received 15 May 1997, Revised 18 July 1997, Accepted 23 July 1997

http://www3.interscience.wiley.com/journal/119157751/abstract?CRETRY=1&SRETRY=0
Crh1p and Crh2p are required for the cross-linking of chitin to β(1-6)glucan in the Saccharomyces cerevisiae cell wall

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)(1) National Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Biochemistry and Genetics, Bethesda, MD 20892, ETATS-UNIS(2) Departamento de Microbiología II, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, ESPAGNE

Résumé / Abstract

In budding yeast, chitin is found in three locations:
-at the primary septum, largely in free form,
-at the mother-bud neck, partially linked to β(1-3)glucan,
-and in the lateral wall, attached in part to β(1-6)glucan.

By using a recently developed strategy for the study of cell wall cross-links, we have found that chitin linked to β(1-6)glucan is diminished in mutants of the CRH1 or the CRH2/UTR2 gene and completely absent in a double mutant.

This indicates that Crh1p and Crh2p, homologues of glycosyltransferases, ferry chitin chains from chitin synthase III to β(1-6)glucan.

Deletion of CRH1 and/or CRH2 aggravated the defects of fks1Δ and gas1Δ mutants, which are impaired in cell wall synthesis.

A temperature shift from 30°C to 38°C increased the proportion of chitin attached to β(1-6)glucan.

The expression of CRH1, but not that of CRH2, was also higher at 38°C in a manner dependent on the cell integrity pathway.

Furthermore, the localization of both Crh1p and Crh2p at the cell cortex, the area where the chitin-β(1-6)glucan complex is found, was greatly enhanced at 38°C.

Crh1p and Crh2p are the first proteins directly implicated in the formation of cross-links between cell wall components in fungi.

http://cat.inist.fr/?aModele=afficheN&cpsidt=18487525

Friday, October 16, 2009

Increased susceptibility to disseminated Candidiasis in interleukin-6 deficient mice

HOME PAGE

Increased susceptibility to disseminated Candidiasis in interleukin-6 deficient mice.

van Enckevoort F, Netea MG, Hermus A, Sweep CG, van der Meer JW, Kullberg BJ; Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1998 Sep 24-27; 38: 296 (abstract no. G-43).
Univ. Hosp. Nijmegen, The Netherlands.
Interleukin-6 (IL-6) is a multifunctional cytokine that regulates multiple aspects of the innate immune response. It has been recently shown that endogenous IL-6 is crucial for an efficient defense against severe infections with Gram- negative and Gram-positive bacteria. The aim of the present study was to investigate the role of endogenous IL-6 in the defense against infection with the yeast Candida albicans. When infected with 3x10(5) CFU/mouse, IL-6 deficient mice (IL-6-/-) had a significantly decreased survival when compared with IL-6+/+ controls (30 vs. 70%, p<0.05). href="http://gateway.nlm.nih.gov/MeetingAbstracts/102188063.html">http://gateway.nlm.nih.gov/MeetingAbstracts/102188063.html

Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats

Auteur(s) / Author(s)ANDO T. (1) ; RIVIER J. (2) ; YANAIHARA H. (1) ; ARIMURA A. (1) ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)(1) United States-Japan Biomedical Research Laboratories, Tulane University Hebert Center, Belle Chasse, Louisiana 70037-3001, ETATS-UNIS(2) Peptide Biology Laboratory, Salk Institute, La Jolla, California 92037, ETATS-UNIS

Résumé / AbstractWe previously reported the elevation of plasma interleukin (IL)-6 activity in response to immobilization stress in rats. To investigate the role of peripheral corticotropin-releasing factor (CRF) in this response, we examined the effects of CRF antagonists on immobilization-induced IL-6 response. Intravenous pretreatment with either [D-Phe12,Nle21,38,CαMeLeu37]-anti-human rat (h/r) CRF12-41 (1.5 mg/kg) or cyclo(30-33)[D-Phe12, Nle21,38,Glu30,Lys33]-h/rCRF12-41 (Astressin, 0.5 mg/kg) attenuated the IL-6 response to immobilization, which confirmed our previous finding that systemic administration of an antiserum against CRF blocked this response. In addition, an intraperitoneal injection of h/rCRF (100 μg/kg) or rat urocortin (10 and 100 μg/kg) increased the plasma IL-6 activity, mimicking the response to immobilization. An intravenous injection of h/rCRF (100 μg/kg) also elevated plasma IL-6 in adrenalectomized rats. These findings suggest that peripheral CRF mediates the plasma IL-6 elevation in response to immobilization.

http://cat.inist.fr/?aModele=afficheN&cpsidt=1770729



Protective effect of alprazolam against sleep deprivation-induced behavior alterations and oxidative damage in mice

Protective effect of alprazolam against sleep deprivation-induced behavior alterations and oxidative damage in mice.

Singh A, Kumar A.
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.

Sleep deprivation is considered as a risk factor for various diseases.

Sleep deprivation leads to behavioral, hormonal, neurochemical and biochemical alterations in the animals.

The present study was designed to explore the possible involvement of GABAergic mechanism in protective effect of alprazolam against 72h sleep deprivation-induced behavior alterations and oxidative damage in mice.

In the present study, sleep deprivation caused
anxiety-like behavior,
weight loss,
impaired ambulatory movements and
oxidative damage
as indicated by
increase in lipid peroxidation,
nitrite level and
depletion of reduced glutathione and catalase activity

in sleep-deprived mice brain.

Treatment with alprazolam (0.25 and 0.5 mg/kg, ip) significantly improved behavioral alterations.

Biochemically, alprazolam treatment significantly restored depleted reduced glutathione, catalase activity,
reversed raised lipid peroxidation and nitrite level.

Combination of flumazenil (0.5 mg/kg) and picrotoxin (0.5 mg/kg) with lower dose of alprazolam (0.25mg/kg) significantly antagonized protective effect of alprazolam.

However, combination of muscimol (0.05 mg/kg) with alprazolam (0.25 mg/kg, ip) potentiated protective effect of alprazolam.

On the basis of these results, it might be suggested that alprazolam might produce protective effect by involving GABAergic system against sleep deprivation-induced behavior alterations and related oxidative damage.

PMID: 18280601 [PubMed - indexed for MEDLINE]


Glutathione
From Wikipedia, the free encyclopedia

Glutathione (GSH) is a tripeptide. It contains an unusual peptide linkage between the amine group of cysteine and the carboxyl group of the glutamate side chain. Glutathione, an antioxidant, helps protect cells from reactive oxygen species such as free radicals and peroxides.[2] Glutathione is also nucleophile at sulfur and attacks poisonous conjugate acceptors.
Thiol groups are kept in a reduced state at a concentration of approximately ~5 mM in animal cells. In effect, glutathione reduces any disulfide bond formed within cytoplasmic proteins to cysteines by acting as an electron donor. In the process, glutathione is converted to its oxidized form glutathione disulfide (GSSG). Glutathione is found almost exclusively in its reduced form, since the enzyme that reverts it from its oxidized form, glutathione reductase, is constitutively active and inducible upon oxidative stress. In fact, the ratio of reduced glutathione to oxidized glutathione within cells is often used scientifically as a measure of cellular toxicity.[3]

Function in animals

GSH is known as a substrate in both conjugation reactions and reduction reactions, catalyzed by glutathione S-transferase enzymes in cytosol, microsomes, and mitochondria. However, it is also capable of participating in non-enzymatic conjugation with some chemicals, as in the case of N-acetyl-p-benzoquinone imine (NAPQI), the reactive cytochrome P450-reactive metabolite formed by paracetamol (or acetaminophen as it is known in the US), that becomes toxic when GSH is depleted by an overdose of acetaminophen.

Glutathione conjugates to NAPQI and helps to detoxify it, in this capacity protects cellular protein thiol groups, which would otherwise become covalently modified; when all GSH has been spent, NAPQI begins to react with the cellular proteins, killing the cells in the process.

The preferred treatment for an overdose of this painkiller is the administration (usually in atomized form) of N-acetyl-L-cysteine, which is processed by cells to L-cysteine and used in the de novo synthesis of GSH.

Glutathione (GSH) participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase.

It is also important as a hydrophilic molecule that is added to lipophilic toxins and waste in the liver during biotransformation before they can become part of the bile. Glutathione is also needed for the detoxification of methylglyoxal, a toxin produced as a by-product of metabolism.

This detoxification reaction is carried out by the glyoxalase system. Glyoxalase I (EC 4.4.1.5) catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-lactoyl-glutathione. Glyoxalase II (EC 3.1.2.6) catalyzes the hydrolysis of S-D-lactoyl-glutathione to glutathione and D-lactic acid.

Glutathione has recently been used as an inhibitor of melanin in the cosmetics industry. In countries like the Philippines, this product is sold as a whitening soap. Glutathione competitively inhibits melanin synthesis in the reaction of tyrosinase and L-DOPA by interrupting L-DOPA's ability to bind to tyrosinase during melanin synthesis.

The inhibition of melanin synthesis was reversed by increasing the concentration of L-DOPA, but not by increasing tyrosinase. Although the synthesized melanin was aggregated within 1 h, the aggregation was inhibited by the addition of glutathione.

These results indicate that glutathione inhibits the synthesis and agglutination of melanin by interrupting the function of L-DOPA. "[17]

silymarin or milk thistle has also demonstrated an ability to replenish glutathione levels!!!

Glutathione is a tightly regulated intracellular constituent and is limited in its production by negative feedback inhibition of its own synthesis through the enzyme gamma-glutamylcysteine synthetase, thus greatly minimizing any possibility of overdosage.

Glutathione augmentation is a strategy developed to address states of glutathione deficiency, high oxidative stress, immune deficiency, and xenobiotic overload in which glutathione plays a part in the detoxification of the xenobiotic in question.

Glutathione deficiency states include, but are not limited to: HIV/AIDS, chemical and infectious hepatitis, prostate and other cancers, cataracts, Alzheimer's, Parkinsons, chronic obstructive pulmonary disease, asthma, radiation poisoning, malnutritive states, arduous physical stress, aging, and has been associated with sub-optimal immune response. Many clinical pathologies are associated with oxidative stress and are elaborated upon in numerous medical references.[44]

Low glutathione is also strongly implicated in wasting and negative nitrogen balance, [45] notably as seen in cancer, AIDS, sepsis, trauma, burns and even athletic overtraining. Glutathione supplementation can oppose this process and in AIDS, for example, result in improved survival rates.[46]

http://en.wikipedia.org/wiki/Glutathione

the 'organ Km' for glutathione in the liver is approximately 0.5 mumol/g of liver, so that the hepatic glutathione conjugation rate is decreased only at severe glutathione depletion.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1132802/

Catalase
From Wikipedia, the free encyclopedia

Catalase is a common enzyme found in nearly all living organisms which are exposed to oxygen, where it functions to catalyze the decomposition of hydrogen peroxide to water and oxygen.[1]

Grey hair
According to recent scientific studies, low levels of catalase may play a role in the greying process of human hair. Hydrogen peroxide is naturally produced by the body and catalase breaks it down. If there is a dip in catalase levels, hydrogen peroxide cannot be broken down. This causes the hydrogen peroxide to bleach the hair from the inside out. Scientists believe this finding may someday lead to "anti" greying treatments for aging hair.[30][31][32]

http://en.wikipedia.org/wiki/Catalase

STRESS-INDUCED SLEEP DEPRIVATION MODIFIES CORTICOTROPIN RELEASING FACTOR (CRF) LEVELS

Copyright © 1997 The Italian Pharmacological Society. Published by Elsevier Science Ltd.
Regular Article

STRESS-INDUCED SLEEP DEPRIVATION MODIFIES CORTICOTROPIN RELEASING FACTOR (CRF) LEVELS AND CRF BINDING IN RAT BRAIN AND PITUITARY*1


PAOLA FADDAa, f1 and WALTER FRATTAb
a ‘B.B. Brodie’ Department of Neuroscience, University of Cagliari, Cagliari, Italy
b Center for Neuropharmacology, National Research Council University of Cagliari, Cagliari, Italy
Accepted 2 April 1997. ;
Available online 15 April 2002.

Abstract

Electroencephalographic (EEG) studies have shown that corticotropin-releasing factor (CRF) administration induces EEG activation, decreases sleep time both in rats and humans and modifies the sleep pattern in sleep deprived rats.

In the present study we have investigated whether CRF neuronal activity could be altered in a situation of disrupted sleep-wake cycle.

Sleep deprivation (SD) was induced by keeping the rat for 72 h on a small platform (7 cm) surrounded by water.

Immediately after the SD period rats were killed and CRF levels and CRF receptor binding were evaluated in different brain areas.

A marked increase in CRF levels was present in the striatum (+224%), limbic areas (+144%) and pituitary (+42%) whereas the hypothalamic CRF content was reduced (−57%).

A significant decrease in CRF binding was found in the striatum (−33%) and pituitary (−38%) of sleep deprived rats.

These results indicate that CRF neuronal activity is stimulated by SD, suggesting that CRF might play an important role in the physiological regulation of the sleep-wake cycle and that an altered CRF neuronal activity might be involved in behavioral modifications related to sleep disturbances.

Author Keywords: Sleep deprivation; corticotropin-releasing factor; limbic system; striatum; rat

*1 De Souza, EBNemeroff, CB
f1 Correspondence to: Paola Fadda, ‘B.B. Brodie’ Department of Neuroscience, University of Cagliari, Via Porcell 4, 09124 Cagliari, Italy.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WP9-45KKVFG-2V&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1051469287&_rerunOrigin=scholar.google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=643478cc8d82373b16a116de18bfa062

Immobilisation stress induces a paradoxical sleep rebound in rat

Immobilisation stress induces a paradoxical sleep rebound in rat

Rampin C, Cespuglio R, Chastrette N, Jouvet M.

Département de Médecine Expérimentale, INSERM U 52, CNRS URA 1195, Université Claude Bernard, Lyons, France.

An immobilisation stress (IS) of 2 h applied to rats at the beginning of the dark period (12 h), i.e. when the animals are more active, induces during the 10 consecutive h a significant rebound (+92%) of paradoxical sleep (PS) while slow-wave sleep state (SWS) is poorly affected. Two h of sleep deprivation, also applied at the beginning of the dark period and realized either by the platform technique or by maintaining the animals awake with gentle handling, do not affect significantly subsequent SWS and PS. Finally, when repetitive IS are inflicted to the animals (one IS of 2 h every 3 days) an attenuation of the PS rebound is observed.

These data suggest that a qualitative aspect of the waking state as in an intense stressful situation might be the source of a hormonal process inducing a PS (paradoxical sleep) excess.

PMID: 1922920 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/1922920

Involvement of stress in the sleep rebound mechanism induced by sleep deprivation in the rat: use of alpha-helical CRH(9-41)

González, M M del C.; Valatx, J-L

Abstract

A previous study demonstrated the efficacy of the corticotropin-releasing hormone (CRH) receptor antagonist, [alpha] -helical CRH (9-41), in blocking the paradoxical sleep increase induced by stress.

In the present study, this peptide was used to evaluate the involvement of the stress component of the sleep deprivation, in the paradoxical sleep rebound.

Rats were subjected for 10 h to the classical water-tank sleep-deprivation technique and were given, every 2 h throughout the sleep deprivation period, intracerebroventricular injections of either 100 [micro]g/5 [micro]I of a-helical CRH (9-41) or vehicle alone.

Continuous recordings showed that antagonist treatment decreased the PS rebound, but not the SWS rebound, following sleep deprivation.

These findings suggest that, in the water-tank sleep deprivation method, stress, acting via CRH activation, is the main factor inducing the paradoxical sleep rebound.

(C) 1998 Lippincott Williams & Wilkins, Inc.

http://journals.lww.com/behaviouralpharm/Abstract/1998/12000/Involvement_of_stress_in_the_sleep_rebound.1.aspx


Sleep deprivation effects on the activity of the hypothalamic–pituitary–adrenal and growth axes: potential clinical implications

Sleep deprivation effects on the activity of the hypothalamic–pituitary–adrenal and growth axes: potential clinical implications

Alexandros N. Vgontzas , George Mastorakos , Edward O. Bixler , Anthony Kales , Philip W. Gold & George P. Chrousos

1 Sleep Research and Treatment Center, Department of Psychiatry, Pennsylvania State University, Hershey, USA, 2 Endocrine Unit, Evgenidion Hospital, Athens University, Athens, Greece, 3 Clinical Neuroendocrinology Branch, National Institute of Mental Health, Bethesda, USA, 4 Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA

Correspondence to: Dr Alexandros N. Vgontzas Sleep Research and Treatment Center, Department of Psychiatry Pennsylvania State University, College of Medicine, 500 University Drive, Hershey, PA 17033, USA. Fax: +1 (717) 531 6491.
Copyright 1999 Blackwell Science Ltd

ABSTRACT

OBJECTIVES

Although several studies have shown that sleep deprivation is associated with increased slow wave sleep during the recovery night, the effects of sleep deprivation on cortisol and growth hormone (GH) secretion the next day and recovery night have not been assessed systematically. We hypothesized that increased slow wave sleep postsleep deprivation is associated with decreased cortisol levels and that the enhanced GH secretion is driven by the decreased activity of the HPA axis.

DESIGN AND SUBJECTS

After four consecutive nights in the Sleep Laboratory, 10 healthy young men were totally deprived of sleep during the fifth night, and then allowed to sleep again on nights six and seven. Twenty-four hour blood sampling was performed serially every 30 minutes on the fourth day, immediately following the previous night of sleep and on the sixth day, immediately after sleep deprivation.

MEASUREMENT

Eight-hour sleep laboratory recording, including electroencephologram, electro-oculogram and electromyogram. Plasma cortisol and GH levels using specific immunoassay techniques.

RESULTS

Mean plasma and time-integrated (AUC) cortisol levels were lower during the postdeprivation nighttime period than on the fourth night (P < class="invisible-anchor" name="h005">

CONCLUSION

We conclude that sleep deprivation results in a significant reduction of cortisol secretion the next day and this reduction appears to be, to a large extent, driven by the increase of slow wave sleep during the recovery night.

We propose that reduction of CRH and cortisol secretion may be the mechanism through which sleep deprivation relieves depression temporarily.

Furthermore, deep sleep has an inhibitory effect on the HPA axis while it enhances the activity of the GH axis. In contrast, sleep disturbance has a stimulatory effect on the HPA axis and a suppressive effect on the GH axis.

These results are consistent with the observed hypocortisolism in idiopathic hypersomnia and HPA axis relative activation in chronic insomnia.

Finally, our findings support previous hypotheses about the restitution and immunoenhancement role of slow wave (deep) sleep.

http://www3.interscience.wiley.com/journal/118881160/abstract?CRETRY=1&SRETRY=0



Saturday, October 10, 2009

Tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release of corticotropin-releasing hormone

The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus.

Patchev VK, Shoaib M, Holsboer F, Almeida OF.Department of Neuroendocrinology, Max Planck Institute for Psychiatry, Munich, Germany.

The ring-A-reduced progesterone derivative 5 alpha-pregnan-3 alpha-ol-20-one (tetrahydroprogesterone) is synthesized under normal physiological conditions in the brain and is a potent modulator of the GABA receptor.

This neurosteroid has significant sedative and anxiolytic properties.

Corticotropin-releasing hormone plays a major role in stress-induced activation of the hypothalamo-pituitary-adrenal axis, and sustained hyperactivity of hypothalamic corticotropin-releasing hormone-producing neurons may be causally related to both, increased pituitary-adrenal secretion and behavioural symptoms observed in anxiety and affective disorders. We investigated the effect of tetrahydroprogesterone on corticotropin-releasing hormone-induced anxiety, the basal and methoxamine-stimulated release of corticotropin-releasing hormone from hypothalamic organ explants in vitro, and adrenalectomy-induced up-regulation of the gene expression of corticotropin-releasing hormone in the hypothalamic paraventricular nucleus in rats. At doses of 5 and 10 micrograms i.c.v., tetrahydroprogesterone counteracted the anxiogenic action of 0.5 microgram of corticotropin-releasing hormone.

Tetrahydroprogesterone did not alter the basal release of corticotropin-releasing hormone in vitro, but suppressed the stimulatory effect of the alpha 1-adrenergic agonist methoxamine on this parameter. Measurements of the steady-state levels of mRNA coding for corticotropin-releasing hormone by quantitative in situ-hybridization histochemistry revealed that tetrahydroprogesterone was equipotent with corticosterone in preventing adrenalectomy-induced up-regulation of peptide gene expression.

Systemic administration of tetrahydroprogesterone also restrained adrenalectomy-induced thymus enlargement.

These results demonstrate that tetrahydroprogesterone has anxiolytic effects that are mediated through interactions with hypothalamic corticotropin-releasing hormone in both, genomic and non-genomic fashions.

http/www.ncbi.nlm.nih.gov/pubmed/7816204

Allopregnanolone (tetrahydroprogesterone)

From Wikipedia, the free encyclopedia

Allopregnanolone, also known as 3α,5α-tetrahydroprogesterone or THP, is an important neurosteroid in the human brain.

It is a metabolite of progesterone and a barbiturate-like modulator of central gamma-aminobutyric acid (GABA) receptors that modify a range of behaviors, including the stress response.

The 5β epimer of this compound is known as pregnanolone, and has very similar properties to allopregnanolone.

Both compounds are found endogenously and have similar hypnotic and anxiolytic effects.

http/en.wikipedia.org/wiki/Allopregnanolone

Tetrahydroprogesterone Attenuates the Endocrine Response to Stress

Neuropsychopharmacology (1996) 15 533-540.

The Neurosteroid Tetrahydroprogesterone Attenuates the Endocrine Response to Stress and Exerts Glucocorticoid-like Effects on Vasopressin Gene Transcription in the Rat Hypothalamus

V K Patchev MD, Ph.D, A H S Hassan B.V.Sc, Ph.D, F Holsboer MD, Ph.D and O F X Almeida Ph.D From the Department of Neuroendocrinology, Max Planck Institute of Psychiatry, Clinical Institute, Munich, GermanyCorrespondence: V K Patchev, Department of Neuroendocrinology, Max Planck Institute of Psychiatry, Clinical Institute, Kraepelinstr. 2, 80804 Munich, Germany. E-mail: patchev@mpipsykl.mpg.de

ABSTRACT

The neurosteroid tetrahydroprogesterone (5-pregnan-3-ol-20-one, allopregnanolone, THP), has been previously shown to counteract the anxiogenic effects of corticotropin-releasing hormone (CRH) and to interfere with noradrenergic and corticosteroid-mediated regulation of CRH release and gene transcription.

Those observations indicated that, besides its sedative and analgesic activity, THP may also affect the neuroendocrine response to stress in a mode resembling that of corticosteroids. To examine this possibility, we compared the ability of THP, its precursor progesterone (P4), and the glucocorticoids dexamethasone (DEX) and corticosterone (CORT) to influence the pituitary-adrenal response to acute emotional stress and the adrenalectomy-induced increase in the gene transcription of the stress-related peptide arginine vasopressin (AVP) and of corticosteroid receptors (MR and GR) in the brain. Pretreatment of rats with a single dose of THP or P4 (50 g/kg) significantly attenuated the elevation of plasma adrenocorticotropin (ACTH) and serum corticosterone after emotional stress; both steroids were, however, less potent than a similar dose of DEX. Administration of 1 mg of THP, CORT, or P4 to adrenalectomized (ADX) rats attenuated the increase in AVP mRNA levels in the ventromedial subdivision of the hypothalamic paraventricular nucleus (PVN), as compared with vehicle-treated ADX rats. However, whereas CORT and P4 influenced the ADX-induced increase in the transcription of both types of corticosteroid receptors in the hippocampus, these were unaffected by THP. In contrast to the glucocorticoids, THP and P4 failed to decrease plasma ACTH levels in rats deprived of endogenous steroids.

These results demonstrate that the neurosteroid THP and its precursor P4 resemble glucocorticoids in their suppression of the pituitary-adrenal response to emotional stress;

however, THP influences the transcription of glucocorticoid-responsive genes in brain structures involved in the regulation of the hypothalamo-pituitary-adrenal system in a fashion that is quite distinct from that obtained with glucocorticoids.

Ó American College of NeuropsychopharmacologyKeywords: Neurosteriods; Progesterone; Glucocorticoids; Vasopressin; Corticosteroid receptors; Stress

http://www.nature.com/npp/journal/v15/n6/abs/1380502a.html

Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides

Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides.

Turnbull AV, Rivier C.Clayton Foundation Laboratory of Peptide Biology, Salk Institute, La Jolla, California 92037, USA.

Corticotropin-releasing factor (CRF) is a 41-amino acid neuropeptide, which is recognized as a critical mediator of complimentary, stress-related endocrine, autonomic, and behavioral responses in mammalian species.

CRF belongs to a family of structurally related peptides including frogskin sauvagine and fish urotensin I.

The effects of CRF and related peptides are mediated by two distinct receptors, which differ in their anatomical distribution, as well as in their pharmacological characteristics.

In addition, CRF is bound with high affinity by a CRF binding protein (CRF-BP), which is a putative inhibitor of CRF action.

CRF is probably not the sole endogenous ligand for CRF receptors or the CRF-BP, since a second mammalian member of the CRF family, urocortin, has recently been identified.

This article describes recent findings with respect to CRF, its receptors, binding protein, and CRF-related peptides, which provide further insights into the role and mechanisms of CRF action in stress responses.

PMID: 9142133 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/9142133

Endogenous substance P inhibits the expression of corticotropin-releasing hormone during a chronic inflammatory stress

Endogenous substance P inhibits the expression of corticotropin-releasing hormone during a chronic inflammatory stress

Copyright © 1995

Published by Elsevier Science Inc.H. S. Chowdreyxa*, P. J. Larsent, M. S. Harbuza, S. L. Lightmana and D. S. Jessopa, a Department of Medicine, University of Bristol, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8Hw, U.K.* School of Chemical and Life Sciences, University of Greenwich, London, U.K.t Department of Medical Anatomy, The Panum Institute, University of, Copenhagen, DenmarkRevised 18 September 1995.
Available online 5 April 2000.

Abstract

We have investigated the effects of a chronic inflammatory stress on substance P (SP) levels in the hypothalami of rats given adjuvant-induced arthritis (AA).

Fourteen days after injection of . substance P concentrations in the paraventricular nucleus (PVN) and median eminence/arcuate nucleus were significantly increased.

In AA rats injected intraperitoneally with the specific neurokinin-1 receptor antagonist RP67580, plasma ACTH and corticosterone concentrations were significantly elevated and corticotropin-releasing hormone (CRH) mRNA in the PVN was increased compared to the AA group which received saline alone. The increases in hypothalamic SP in AA, together with the data demonstrating that HPA axis activity is enhanced in AA following injection of a SP antagonist, are consistent with the hypothesis that SP is acting as an inhibitor of CRH expression in this model of chronic inflammatory stress.Author Keywords: substance P; CRH; ACTH; corticosterone; RP67580

http://www.sciencedirect.com/science...d93c9300c9e 5
 
Veraland

| Home | Fashion | Global Politics | The Black Sea | Poetry | Dance | Endocrinology | News | Comments |Contact| Archive |